Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-02

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of our study was to determine the modifications of blood myostatin and activin A concentrations associated with head and neck cancers. Secondary objectives consisted in studying their influence on the occurrence of cachexia, bringing the proof of a tumoral secretion of these factors, and then determining the effect of tumor removal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

NCT04046575

Esophagus Cancer Esophageal Cancer Cancer of the Esophagus

ACTIVE_NOT_RECRUITING PHASE1

Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia

NCT05954117

Esophageal Adenocarcinoma

NOT_YET_RECRUITING NA

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

NCT06889402

Esophageal Cancer

NOT_YET_RECRUITING

Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only

NCT00653107

Esophageal Neoplasm

TERMINATED PHASE3

AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

NCT05594914

Esophageal Squamous Cell Carcinoma

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myostatin and activin A, two members of the superfamily TGF-β, have been shown to play a role on skeletal muscle mass regulation. In Humans, high plasma concentrations of activin A were observed in cancer patients, especially in cachectic subpopulations, suggesting their involvement in the development of cachexia.

55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group. The patients underwent a complete nutritional assessment and multiple samples : blood before and 7 days after surgery, skeletal muscle biopsies, tumor biopsies. Plasma concentrations of myostatin, activin and follistatin were measured before and after tumor removal surgery. Concentrations of myostatin, activin and follistatin were also measured in an incubation medium of a tumor biopsy. Activin A and follistatin plasma concentrations were significantly increased in the cancer group (320 vs. 203 pg/ml ; p \<0.001) (3593 vs 2148 pg/ml ; p \<0.001), while myostatin plasma concentration was significantly decreased in this group (1542 vs. 2100 pg/ml ; p = 0.010). Surprisingly, data of the 7th postoperative day showed an increase in plasma activin A concentration (379 vs 320 pg /ml ; p \<0.001) while concentrations of myostatin and follistatin were not modified. A high postoperative systemic inflammation is one hypothesis to explain these later results. Myostatin, activin A and follistatin proteins were systematically detected in the medium of tumor a 48 hour-incubation period, providing a strong proof of the tumor production of these factors by squamous cell carcinoma. The activin A/myostatin/follistatin is modified in the context of head and neck cancer. Activin A particularly seems to play a role in the occurrence of cachexia while follistatin could have a protective role for skeletal muscle mass. This system could aimed in therapeutic ways to reduce cachexia in a context of cancer in order to improve the quality of life and survival of patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cachexia Squamous Cell Carcinoma Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Squamous cell carcinoma

55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.

Tumor removal

Intervention Type PROCEDURE

Surgery

Control group

55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.

Tumor removal

Intervention Type PROCEDURE

Surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumor removal

Surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For case group :

* head and neck cancer
* squamous cell carinoma only
* head and neck surgery chosen as treatment of cancer
* age 18-75

For control group :

* Neck surgery for non oncologic disease
* age 18-75

Exclusion Criteria

* heart failure, respiratory failure (requiring a long-term oxygen therapy), chronic renal failure (MDRD clearance \< 60 ml/min), moderate or severe chronic obstructive pulmonary disease and insulin-dependent diabeta for the two groups
* cachexia for control group

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes